We are live on ! Find out more
P

Pfizer Portfolio holdings

AUM $239M
1-Year Est. Return 232.47%
This Fund
S&P 500
This Quarter Est. Return
+54.78%
1 Year Est. Return
+232.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$437M
AUM Growth
-$139M
Cap. Flow
-$213M
Cap. Flow %
-48.71%
Top 10 Hldgs %
95.12%
Holding
21
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$756K

Top Sells

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$214M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
1
BioNTech
BNTX
$22.9B
$164M 37.39%
1,658,361
-2,000,000
-55% -$214M
ORIC icon
2
Oric Pharmaceuticals
ORIC
$1.15B
$64.5M 14.75%
5,376,344
– –
TRML
3
DELISTED
Tourmaline Bio
TRML
$60.8M 13.91%
1,272,214
– –
ARVN icon
4
Arvinas
ARVN
$518M
$29.5M 6.73%
3,457,815
– –
ALLO icon
5
Allogene Therapeutics
ALLO
$649M
$27.3M 6.25%
22,032,040
– –
CELC icon
6
Celcuity
CELC
$4.21B
$17.3M 3.95%
349,406
– –
PYXS icon
7
Pyxis Oncology
PYXS
$168M
$15.6M 3.57%
7,032,770
– –
WVE icon
8
Wave Life Sciences
WVE
$1.09B
$13.7M 3.14%
1,875,000
– –
ZURA icon
9
Zura Bio
ZURA
$516M
$12.9M 2.94%
2,970,022
– –
CRBU icon
10
Caribou Biosciences
CRBU
$145M
$10.9M 2.5%
4,690,431
– –
BHVN icon
11
Biohaven
BHVN
$2.03B
$7.59M 1.74%
505,645
– –
CRDF icon
12
Cardiff Oncology
CRDF
$66.5M
$4.97M 1.14%
2,411,575
– –
SPRO icon
13
Spero Therapeutics
SPRO
$67.7M
$4.44M 1.02%
2,362,348
– –
ZNTL icon
14
Zentalis Pharmaceuticals
ZNTL
$337M
$1.44M 0.33%
953,834
– –
NXTC icon
15
NextCure
NXTC
$16.8M
$924K 0.21%
157,646
+144,509
+1,100% +$756K
ANTX icon
16
AN2 Therapeutics
ANTX
$193M
$908K 0.21%
715,295
– –
QTTB icon
17
Q32 Bio
QTTB
$466M
$550K 0.13%
277,777
– –
EPIX
18
DELISTED
ESSA Pharma
EPIX
$320K 0.07%
1,675,000
– –
BOLT icon
19
Bolt Biotherapeutics
BOLT
$7.67M
$167K 0.04%
31,305
– –
DNA icon
20
Ginkgo Bioworks
DNA
$528M
$42.7K 0.01%
2,928
– –
SENS icon
21
Senseonics Holdings Inc
SENS
$263M
$18.9K ﹤0.01%
2,171
– –

Similar funds

DCC
Dow Chemical Company Midland, Michigan $239M AUM 13.16% 1-Year Est. Return
OCERS
Orange County Employees Retirement System Santa Ana, California $239M AUM
WWA
Wealth Watch Advisors Englewood, Colorado $239M AUM 21.17% 1-Year Est. Return
MFC
Mechanics Financial Corp Mansfield, Ohio $239M AUM 25.61% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return
GCA
Genesee Capital Advisors Auburn, New York $239M AUM 20.45% 1-Year Est. Return
FWP
Forefront Wealth Partners Austin, Texas $239M AUM 16.12% 1-Year Est. Return
LOM
LTS One Management New York $239M AUM 18.42% 1-Year Est. Return

Pfizer's Q3 2025 Portfolio in Review

As of Q3 2025, Pfizer held 21 positions worth $437M, down 24% from $576M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Pfizer withdrew a net $213M in Q3 2025, reducing 1 holding. Its largest reduction was BioNTech, cutting an estimated $214M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pfizer added an estimated $756K to NextCure.

  • Pfizer added most to NextCure in Q3 2025, an estimated $756K increase.
  • Pfizer's biggest Q3 2025 reduction was BioNTech, cutting an estimated $214M.
  • Pfizer's ten largest holdings make up 95% of its $437M portfolio in Q3 2025.
  • Pfizer opened 0 new positions and closed 0 in Q3 2025.
  • Pfizer's portfolio value fell 24% quarter-over-quarter to $437M.

Based on Pfizer's 13F filing for Q3 2025, filed 13 Nov 2025.